NCT07854275Completed
Biomarkers, Abdominal Muscle, and Frailty in CKD
The Association of Total Oxidant/Antioxidant Capacity and MCP-1 Markers With Abdominal Muscle Thickness and Frailty in Patients With Stage 3-5 Chronic Kidney Disease
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
In chronic kidney disease (CKD), inflammation and oxidative stress are important processes that may be associated with the development of muscle loss and frailty. The aim of this study is to investigate the relationships between serum MCP-1, total antioxidant status (TAS), and total oxidant status (TOS)-markers of inflammation and oxidative stress-and abdominal muscle thickness and frailty, as assessed by ultrasound, in stage 3-5 CKD patients not receiving dialysis. In addition, the study aims to assess participants' physical performance, kinesiophobia, and quality of life and to examine these characteristics according to CKD stages.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 88 (actual)
- First submitted
- 28 Sept 2026
- Start date
- 15 Jan 2025
- Primary completion date
- 15 May 2025
- Lead sponsor
- Ankara City Hospital Bilkent
- Diseases
- Chronic kidney disease
- NCT number
- NCT07854275
What you commit to
- Study type: Observational
- Participants enrolled: 88
- From 15 Jan 2025 to the primary completion date, 15 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- those with acute infection
- malignancy
- uncontrolled hypertension
- severe heart failure
- a history of neurological disease (stroke, cerebral hemorrhage)
- those taking steroids; and patients with chronic inflammatory diseases.
Other
- Patients undergoing dialysis
- severe anemia (Hb \< 7)
- pregnant women
- patients with immunodeficiency
Who the study is looking for
- the ages of 18 and 70
- have been diagnosed with stage 3, 4, or 5 chronic kidney disease (CKD) for at least 6 months
- have been receiving stable medical treatment for the past 6 months
- be in a clinically stable condition
- have no cognitive impairment
- be literate; and have no vision or hearing problems that would prevent the administration of the scales
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samsun Training and Research hospital Coordinator of this site? Confirm its status | Samsun | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.